ADK enters the final stretch before its May 28 earnings release on the back of a quiet but telling cluster of insider purchases — and a stock that has slipped 13% over the past month to C$0.235.
The most meaningful angle on DIAGNOS right now is what management did with their own money. In December 2025, three senior insiders — President and CEO André Larente, COO Yves-Stéphane Couture, and director Michael Braeuel — all bought shares at C$0.30, collectively adding roughly 317,000 shares and committing just under C$69,000 (USD). That is the entire net insider position over the past 90 days, and all three transactions were on the same date, giving them the character of a coordinated expression of confidence. The current price of C$0.235 means every one of those insiders is underwater on the trade — a detail worth noting as the next earnings date approaches.
Short interest is too small to drive the narrative here. At just 0.028% of the free float, fewer than 32,000 shares are estimated short — a trivial figure for a company with over 120 million shares outstanding. The 83% week-on-week jump in short shares is a statistical artefact of a thin market rather than a meaningful directional bet. Borrowing costs have eased sharply, dropping more than 80% over the past month to around 1.1%, and lending availability is comfortably loose. There is no short-side pressure worth flagging.
The lending market does carry one unusual footnote. On April 14, the lending pool briefly hit full utilisation — every available share was out on loan — before quickly reverting to the current relaxed 5.5% level. That spike appears to have been a one-day anomaly rather than a sustained demand signal, given how fast it unwound. The ORTEX short score has drifted lower, easing from 45.9 on April 14 back to 26.5 by April 24, reinforcing the view that whatever drove that brief tightening has since dissipated.
On the corporate front, April brought two pieces of substantive news. DIAGNOS completed its renewal of US FDA Medical Device Establishment Registration on April 2, keeping its CARA diabetic retinopathy screening platform in good regulatory standing in the US market. A week later, the company issued an update on CARA sales and regulatory activities across multiple jurisdictions. These are incremental rather than transformative, but they matter for a pre-revenue-scale medtech: continued regulatory maintenance and commercialisation progress are the milestones the market is watching to determine whether CARA can translate clinical validation into meaningful revenue. No analyst coverage is current enough to cite responsibly — the lone buy rating on file is from July 2024, which is too stale to carry weight here.
Correlated peers had a mixed week. TDOC and ONMD both closed near flat to modestly positive on the day, while health-tech peers on other exchanges saw sharper moves in both directions. ADK's own weekly decline of 2.1% sits within the range of peer volatility rather than standing out as an outlier. The next set piece is the May 28 earnings release — with insider buyers already on record at a 28% premium to the current price, the key question is whether the CARA commercialisation update in that report gives them any reason to feel vindicated.
See the live data behind this article on ORTEX.
Open ADK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
